Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Association between CYP2C19 genotype and proguanil oxidative polymorphism.|
|Citation:||British Journal of Clinical Pharmacology, 1997; 43(6):659-660|
|Publisher:||BLACKWELL SCIENCE LTD|
|Abstract:||<h4>Aims</h4>To examine the relationship between proguanil metabolism and the number of mutations in CYP2C19 by comparing the CYP2C19 genotype and proguanil phenotype of 10 subjects.<h4>Methods</h4>Partial clearance and urinary metabolic ratio data were obtained from a previous study of 10 subjects . Analysis of CYP2C19 genotypes was performed using PCR amplification followed by restriction endonuclease digestion of genomic DNA from a blood sample.<h4>Results</h4>The intrinsic partial clearance of PG to CG ranged from 0.41-10.11 h-1, and was related to the number of functional CYP2C19 alleles present. Genotypic PMs had metabolic ratios > 13, while genotypic heterozygote EMs had metabolic ratios < 9.<h4>Conclusions</h4>Proguanil may be a suitable phenotyping probe for the CYP2C19 genetic polymorphism, however the exact antimode of the urinary metabolic ratio chosen to separate poor and extensive metabolisers needs further investigation.|
|Keywords:||Humans; Cytochrome P-450 Enzyme System; Aryl Hydrocarbon Hydroxylases; DNA Restriction Enzymes; Mixed Function Oxygenases; DNA; Antimetabolites; Administration, Oral; Polymerase Chain Reaction; Gene Expression Regulation, Enzymologic; Genotype; Heterozygote; Phenotype; Polymorphism, Genetic; Alleles; Asian Continental Ancestry Group; European Continental Ancestry Group; Proguanil; Cytochrome P-450 CYP2C19|
|Appears in Collections:||Pharmacology publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.